CD8A and hepatocellular carcinoma: Accordingly, targeting the CTLA-4+ CD8+ T cell population with anti-CTLA-4 antibodies in immunoassay screenings, successfully restored the intensity of TAA responses in samples from MASH-HCC patients (Inada et al., 2019).